Biotechnology

Filter

Current filters:

None

Popular Filters

1 to 25 of 2300 results

Amgen files for US approval of cholesterol drug evolocumab

28-08-2014

USA-based Amgen, the world's leading independent biotech firm, has filed a Biologics License Application…

AmgenBiotechnologyCardio-vascularevolocumabRegulationUSA

Green Cross Neulapeg biosimilar approved in South Korea

28-08-2014

South Korea’s Green Cross says that the country’s Ministry of Food and Drug Safety has granted marketing…

AmgenAsia-PacificBiosimilarsBiotechnologyGreen CrossNeulapegNeulastaOncologyRegulation

AusBiotech welcomes Greens' push for quarterly payments on R&D Tax Incentive

AusBiotech welcomes Greens' push for quarterly payments on R&D Tax Incentive

28-08-2014

Trade group AusBiotech says it fully supports the Australian Greens’ moving of an amendment in the…

AustraliaBiotechnologyFinancialResearch

China monoclonal antibody research forecast to increase

China monoclonal antibody research forecast to increase

28-08-2014

Several Chinese large-scale pharmaceutical enterprises have devoted themselves to research and development…

BiosimilarsBiotechnologyChinaHengrui MedicineMarkets & MarketingQilu PharmResearchShanghai Pharmaceuticals

Analysis of Roche’s InterMune acquisition

Analysis of Roche’s InterMune acquisition

28-08-2014

The acquisition of InterMune gives Swiss drug major Roche a substantial opportunity, owing to the Breakthrough…

BiotechnologyIdiopathic pulmonary fibrosisInterMuneMergers & AcquisitionspirfenidonePulmozymeRespiratory and PulmonaryRocheSwitzerlandXolair

FDA priority review for Amgen’s ivabradine in CHF

FDA priority review for Amgen’s ivabradine in CHF

27-08-2014

The US Food and Drug Administration has granted priority review designation for US biotech giant Amgen’s…

AmgenBiotechnologyCardio-vascularivabradineRegulationServierUSA

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

27-08-2014

The UK’s drugs watch dog, the National Institute for Health and Care Excellence (NICE), has recommended…

Biogen IdecBiotechnologyCNS DiseasesMultiple sclerosisRegulationTecfideraUK

Merck Serono starts building $105 million plant in Nantong, China

Merck Serono starts building $105 million plant in Nantong, China

27-08-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, has started construction on its new pharmaceutical…

BiotechnologyChinaMerck KGaAMerck SeronoNantongPharmaceutical manufacturing facilityProduction

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

26-08-2014

Canadian regulator Health Canada has approved US Biotech major Biogen Idec’s Eloctate (antihemophilic…

Biogen IdecBiotechnologyCanadaEloctateHematologyRegulationSwedish Orphan Biovitrum

Advaxis and Merck & Co collaborate on prostate cancer

Advaxis and Merck & Co collaborate on prostate cancer

26-08-2014

US cancer immunotherapies firm Advaxis has entered into a clinical trial collaboration agreement with…

AdvaxisADXS-PSABiotechnologyLicensingMerck & CoOncologypembrolizumabResearch

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

26-08-2014

Ireland-headquartered biotech firm Alkermes has submitted a New Drug Application to the US Food and Drug…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyNeurologicalRegulationUSA

Regado Biosciences permanently halts REGULATE-PCI trial

Regado Biosciences permanently halts REGULATE-PCI trial

25-08-2014

US-based cardiovascular specialist Regado Biosciences Regado Biosciences has announced the permanent…

BiotechnologyCardio-vascularRegadoResearchRevolixys

ViaCyte gets $20 million in deal with Janssen

ViaCyte gets $20 million in deal with Janssen

22-08-2014

Privately held US regenerative medicine company ViaCyte has entered into a rights agreement with Janssen…

BiotechnologyDiabetesEndocrine systemFinancialJanssenJohnson & JohnsonLicensingUSAVC-01ViaCyte

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

21-08-2014

Surveyed managed care organizations (MCOs) anticipate that their costs of covering biologic treatments…

Anti-Arthritics/RheumaticsBiotechnologyFinancialHealthcareImmunologicals

Positive Ph III data for Amicus’ migalastat as Fabry monotherapy

Positive Ph III data for Amicus’ migalastat as Fabry monotherapy

21-08-2014

US biopharma company Amicus Therapeutics has revealed positive 18-month data from its second Phase III…

Amicus TherapeuticsBiotechnologymigalastatRare diseasesRegulationResearch

AstraZeneca to collaborate with Illumina on gene sequencing panel for diagnostic tests

AstraZeneca to collaborate with Illumina on gene sequencing panel for diagnostic tests

21-08-2014

Anglo-Swedish drug major AstraZeneca is to collaborate with gene sequencing company Illumina to develop…

AstraZenecaBiotechnologyGeneticsIlluminaOncologyPersonalized healthcareResearch

1 to 25 of 2300 results

Back to top